Bird Flu
CytoDyn Advised of Protocol Deviation in Bird Flu Vaccine Study
Published in Vaccine Weekly, July 25th, 2007
CytoDyn, Inc. (Pink Sheets:CYDY), as the study sponsor, has been advised of a protocol deviation that occurred in a murine study of dosing and immunogenicity for DNA-based bird flu vaccines. The purpose of the study is to provide empirical validation of the Company's design for a clinical trial, or to identify any needed modifications to the clinical trial design. CytoDyn's clinical trial is intended as a preliminary demonstration of safety and efficacy (through the standard marker of protective antibodies) both for the Company's family of DNA flu vaccines, and for a proprietary method of using such vaccines.
The 42-week study (NAWI1618-07-01) uses 10 groups of BALB/C...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2007-07-25)
More Articles from Vaccine Weekly
- Cancer Vaccines
Biodesign Institute leads innovative project to prevent cancer - Cancer Vaccines
Study Looks at Whether Vaccines Promote False Sense of Security - HIV/AIDS
Japan's DNAVEC and IAVI partner on novel AIDS vaccine strategy - Bird Flu
BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine - Bird Flu
Carrington Subsidiary DelSite Enters Into Consulting Agreement with Biologics Consulting Groups, Inc. - Cancer Vaccines
BioCurex Comments on Genetic Testing and RECAF Technology - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
